[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620725":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":37,"locations":43,"responsibleParty":65,"collaborators":36,"id":67,"slug":36,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":36,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":46,"whyStopped":36,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},{"fullName":5,"class":6},"Angitia Biopharmaceuticals","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1 (Japanese)","EXPERIMENTAL","One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of low dose AGA2118.",[13],"Drug: AGA2118",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2 (Japanese)","One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of medium dose AGA2118.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3 (Japanese)","One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of high dose AGA2118.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4 (Caucasian)","Healthy Caucasian participants will receive a single administration of high dose AGA2118.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Cohort 5 (Chinese)","Healthy Chinese participants will receive a single administration of high dose AGA2118.",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","AGA2118","Participants will receive AGA2118 administered by subcutaneous injection",[9,15,19,23,27],null,[38],{"name":39,"role":40,"phone":41,"phoneExt":36,"email":42},"Kimberly Brown","CONTACT","818-862-2068","clinicaltrials@angitiabio.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Los Angeles EPCU","RECRUITING","Glendale","California","91206","United States",{"type":52,"coordinates":53},"Point",[54,55],-118.25508,34.14251,{"lat":55,"lon":54},[58,62],{"name":59,"role":40,"phone":60,"phoneExt":36,"email":61},"Stephanie Gill","888-228-7425","study.losangeles@parexel.com",{"name":63,"role":64,"phone":36,"phoneExt":36,"email":36},"Esther Yoon","PRINCIPAL_INVESTIGATOR",{"type":66,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100620725",false,"NCT07361354","A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)","A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of AGA2118 in Healthy Japanese, Chinese, and Caucasian Participants","ATLAS","Inclusion Criteria:\n\n* Healthy males or females, aged 18 to 65 years\n* 25-hydroxyvitamin D ≥30 ng\u002FmL and agree to taking calcium and vitamin D supplements during the study\n* Meet the criteria for Japanese, Chinese, or Caucasian ethnicity\n\nExclusion Criteria:\n\n* Participating or have participated in another clinical trial within the past 6 months\n* Any bone fracture within the past 6 months\n* History of myocardial infarction or stroke within the past 12 months\n* Malignancy within the past 5 years\n* Current hyper- or hypocalcemia\n* Pregnant or breastfeeding women, or women planning to become pregnant during the study",true,"ALL","18 Years","65 Years",{"count":79,"type":80},30,"ESTIMATED","INTERVENTIONAL",[83],"PHASE1","This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants",[86,87],"Healthy Participants","Pharmacokinetic Study",[89,90],"Ethnobridging","Healthy volunteer","2026-01-16",{"date":93,"type":94},"2026-01-23","ACTUAL",{"date":96,"type":94},"2026-01-05",{"date":98,"type":80},"2026-11",{"name":100,"class":6},"Angitia Incorporated Limited",1]